Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Allgenesis Reports Positive Data from US Trial of Diabetic Macular Edema Therapy

publication date: May 24, 2023

Taiwan’s Allgenesis Biotherapeutics reported positive early data from a US Phase IIa trial of AG-77305 to treat Diabetic Macular Edema (DME). AG-73305 is a bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins. It contains a VEGF-trap and a disintegrin that blocks various key integrin receptors. The molecule is intended to treat DME, other forms of macular edema and additional retinal diseases. In a 2021 deal, Shanghai AffaMed acquired exclusive China rights for AG-73305 to treat DME and all other ophthalmic indications. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital